A powerful congressional committee has approved a spending bill and an attached report that expresses concerns about health risks from cannabis-derived products, while separately encouraging research into the therapeutic benefits of psychedelics.
The report advanced by the House Appropriations Committee on Wednesday says there has been a “proliferation” of cannabis products that “pose potential health and safety risks to consumers through misleading, unsubstantiated, and false claims” that they can treat serious illnesses.
“Such products may also be contaminated with harmful substances,” the report, which is attached to the Fiscal Year 2027 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill, says.
Citing the Federal Food, Drug, and Cosmetic Act (FFDCA), it calls on the Food and Drug Administration (FDA) to “take enforcement action against the manufacturers of any cannabis products marketed with unlawful therapeutic claims to preserve the integrity of the drug development and approval processes.”
“Cannabidiol Oil Enforcement.—The Committee is concerned about the proliferation of products marketed in violation of the FFDCA, including products containing derivatives of the cannabis plant. The Committee is aware that non-FFDCA-compliant products pose potential health and safety risks to consumers through misleading, unsubstantiated, and false claims that cannabis and cannabis derivatives
Read full article on Marijuana Moment
